Table 1 Baseline characteristics of SLE patients, SJS patients, and control subjects
|  | SLE patients (n = 23) | Sjogren's syndrome (n = 9) | Healthy controls (n = 20) |
|---|---|---|---|
Age (y) (mean ± SD) | 44.38 ± 10.87 | 56.56 ± 13.86 | 48.37 ± 12.01 |
Male /female | 2/21 | 1/8 | 6/14 |
Clinical symptoms | Ï® | Â | Â |
 Constitutional | 9 | 0 | --- |
 Muco-cutaneous involvement | 2 | 0 | --- |
 Neurological involvement | 14 | 7 | --- |
 Musculo-skeletal involvement | 15 | 2 | --- |
 Cardio-respiratory involvement | 2 | 0 | --- |
 Renal involvement | 3 | 0 | --- |
 Hematologic involvement | 6 | 0 | --- |
Median (IQR) SLEDAI-2Â K | 11 (6-14) | Â | --- |
Mean dosage of medication (mg/day) | ξ |
| Â |
 Prednisolone | 21 (mg/day) (n = 15) | 3.3 (mg/day) (n = 5) | --- |
 Hydroxychloroquine | 300 (mg/day) (n = 17) | 150 (mg/day) (n = 5) | --- |
 Azathioprine | 50 (mg/day) (n = 1) | 0 | --- |
 Mycophenolate | 1080 (mg/day) (n = 1) | 0 | --- |
 Cyclophosphamide | 500 (mg/month) (n = 2) | 0 | --- |
 Cyclosporine | 50 (mg/day) (n = 3) | 0 | --- |
17 patients who had more than one clinical symptom.- ξ12 patients who took more than one medication.
4 patients who took more than one medication.- Abbreviations: SLE Systemic lupus erythematosus, SJS Sjogren’s syndrome, IQR Inter-quartile range, SLEDAI-2 K Systemic lupus erythematosus disease activity index 2000.
17 patients who had more than one clinical symptom.